GlassScriptPhysician profile
Shaun A Hussain
NPI 1902067796
$39,919.85
in general payments reported to CMS, 2019-2025
19 companies · $588 in 2025
The $588 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $5,130 · 2021: $5,782 · 2022: $9,669 · 2023: $1,366 · 2024: $761 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,535 · Consulting Fee: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.74 |
| Consulting Fee | $1,180.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $20,601.20 | 2019-2021 | |
| Radius Health, INC. | $14,575.00 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $1,453.02 | 2022-2025 | Epidiolex |
| West Therapeutics Development, LLC | $1,050.00 | 2019 | |
| Aquestive Therapeutics, INC. | $552.63 | 2019-2020 | |
| Ucb, INC. | $516.88 | 2020-2025 | Fintepla, Nayzilam, Briviact |
| Takeda Pharmaceuticals U.S.A., INC. | $480.00 | 2024 | |
| Lundbeck LLC | $160.00 | 2025 | |
| Livanova USA, INC. | $152.20 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Sk Life Science, INC. | $144.85 | 2024 | |
| Pyros Pharmaceuticals, INC. | $114.37 | 2023 | Vigpoder |
| Neurelis, INC. | $48.70 | 2021-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $36.90 | 2025 | Daybue |
| Immedica Pharma US, INC. | $27.44 | 2022 | |
| Travere Therapeutics, INC. | $6.66 | 2019-2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.